Iron overload cardiomyopathies: new insights into an old disease
- PMID: 8086319
- DOI: 10.1007/BF00877096
Iron overload cardiomyopathies: new insights into an old disease
Abstract
Iron overload cardiomyopathy is an old disease that has evolved from a rare undiagnosable and untreatable condition to a now much more common, diagnosable, and potentially treatable condition. Pathologically it is due to a direct free iron effect on the myocytes, and not due to interstitial infiltration. This also implies that the disease process is reversible if the tissue iron concentration can be controlled. The advent of magnetic resonance imaging and future genetic identification can identify the population at risk. Chelation therapy, including newer forms of oral chelators, likely will be more commonly available to benefit an ever increasing number and spectrum of the population. Further active research will be needed to improve our pathophysiological understanding and clinical treatment of this increasingly common condition.
Similar articles
-
Iron overload disorders: natural history, pathogenesis, diagnosis, and therapy.Crit Rev Clin Lab Sci. 1983;19(3):205-66. doi: 10.3109/10408368309165764. Crit Rev Clin Lab Sci. 1983. PMID: 6373141 Review.
-
[Hemochromatosis].Ann Med Interne (Paris). 1981;132(6):413-33. Ann Med Interne (Paris). 1981. PMID: 7032384 Review. French. No abstract available.
-
Successful Treatment of Iron-Overload Cardiomyopathy in Hereditary Hemochromatosis With Deferoxamine and Deferiprone.Can J Cardiol. 2016 Dec;32(12):1574.e1-1574.e3. doi: 10.1016/j.cjca.2016.07.589. Epub 2016 Jul 28. Can J Cardiol. 2016. PMID: 27789107
-
[Genetic iron overloads and hepatic insulin-resistance iron overload syndrome: an update].Rev Med Interne. 2009 Jan;30(1):35-42. doi: 10.1016/j.revmed.2008.05.004. Epub 2008 Jun 26. Rev Med Interne. 2009. PMID: 18584923 Review. French.
-
Thalassemia.Hematology Am Soc Hematol Educ Program. 2004:14-34. doi: 10.1182/asheducation-2004.1.14. Hematology Am Soc Hematol Educ Program. 2004. PMID: 15561674 Review.
Cited by
-
Secondary and Infiltrative Cardiomyopathies.Curr Treat Options Cardiovasc Med. 2000 Oct;2(5):373-384. doi: 10.1007/s11936-000-0033-y. Curr Treat Options Cardiovasc Med. 2000. PMID: 11096542
-
Heart Rate Recovery as a Novel Test for Predicting Cardiac Involvement in Beta-Thalassemia Major.Acta Cardiol Sin. 2017 Jul;33(4):410-419. doi: 10.6515/acs20161104a. Acta Cardiol Sin. 2017. PMID: 29033512 Free PMC article.
-
Investigation of cardiomyopathy using cardiac magnetic resonance imaging part 1: Common phenotypes.World J Cardiol. 2012 Apr 26;4(4):103-11. doi: 10.4330/wjc.v4.i4.103. World J Cardiol. 2012. PMID: 22558489 Free PMC article.
-
The role of endocytic pathways in cellular uptake of plasma non-transferrin iron.Haematologica. 2012 May;97(5):670-8. doi: 10.3324/haematol.2011.054858. Epub 2011 Dec 16. Haematologica. 2012. PMID: 22180428 Free PMC article.
-
Overview of Restrictive Cardiomyopathies.Methodist Debakey Cardiovasc J. 2022 Mar 14;18(2):4-16. doi: 10.14797/mdcvj.1078. eCollection 2022. Methodist Debakey Cardiovasc J. 2022. PMID: 35414858 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical